Predictors of adverse diastolic remodeling in non-diabetic patients presenting with ST-elevation myocardial

Lawien Al Ali1, Hilde E Groot2, Solmaz Assa2

  • 1Department of Cardiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30.001, 9700 RB, Groningen, the Netherlands. l.al.ali@umcg.nl.

Insights

Female gender, multivessel disease, and microvascular damage predict diastolic remodeling after ST-elevation myocardial infarction (STEMI). These factors, along with age and hypertension, influence diastolic function post-STEMI.

Area of Science:

  • Cardiology
  • Cardiac Imaging
  • Myocardial Infarction Research

Background:

  • Adverse systolic remodeling post-ST-elevation myocardial infarction (STEMI) is linked to poor outcomes.
  • Diastolic remodeling following STEMI is less understood.
  • Identifying predictors of diastolic remodeling is crucial for patient management.

Purpose of the Study:

  • To identify factors associated with diastolic remodeling after STEMI.
  • To investigate clinical, angiographic, and biomarker predictors.
  • To understand the progression of diastolic dysfunction post-myocardial infarction.

Main Methods:

  • Echocardiography in 267 non-diabetic STEMI patients (GIPS-III trial).
  • Assessed diastolic remodeling using E/e' changes from hospitalization to 4-month follow-up.
  • Multivariable regression models adjusted for age and sex.

Main Results:

  • Female gender, multivessel disease, and higher glucose predicted higher E/e' at 4 months.
  • Lower myocardial blush grade, AST, and NT-proBNP predicted increased E/e' over time.
  • Older age and hypertension predicted worse pre-existing diastolic function.

Conclusions:

  • Female gender, multivessel coronary artery disease, and microvascular damage are key predictors of adverse diastolic remodeling post-STEMI.
  • Pre-STEMI factors like age and hypertension may worsen baseline diastolic function.
  • Understanding these predictors can guide therapeutic strategies for post-STEMI patients.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
20
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
44
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
25
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
15
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
16